



## Supplementary Figure 1. Levels of soluble biomarkers at baseline and after eight –day therapy.

(A)



(B)



### Figure legends

Fig. S1. The results are expressed as sCD14 (A) and D-dimer (B) levels at day 0 and day 8, for every study group. Every black line represents a patient on follow up. Differences along the follow-up were studied using the Wilcoxon test; significant values are depicted with an asterisk.

**Supplementary Table 1. Baseline characteristics of the patients with follow-up at week 12.**

Characteristics	MCT- (n=11) <sup>a</sup>	MCT+ (n=24) <sup>b</sup>	Control Group (n=13) <sup>c</sup>	<i>p</i> (a vs c) <sup>*</sup>	<i>p</i> (b vs c) <sup>**</sup>
Age (years)	43 [38 — 45]	44 [41 — 48]	33 [28 — 47]	ns	0.048
Male sex, n (%)	9 (81.8)	16 (66.7)	10 (76.9)	ns	ns
Time from HIV-diagnosis (weeks)	858 [658 — 1014]	950 [616 — 1061]	10 [6 — 41]	<0.001	<0.001
CDC clinical stage C, n (%)	4 (36.4)	3(12.5)	2 (15.4)	ns	ns
CD4+ T-cells (cells/mm <sup>3</sup> )	41 [17 — 162]	332 [234 — 487]	167 [62 — 348]	0.056	0.016
Nadir CD4+ T-cells (cells/mm <sup>3</sup> )	33 [4 — 84]	217 [145 — 302]	121 [55 — 348]	0.005	ns
CD8+ T-cells (cells/mm <sup>3</sup> )	424 [372 — 1479]	826 [609 — 982]	677 [546 — 968]	ns	ns
HIV-Viral Load (Log <sub>10</sub> RNA-copies/ml)	4.9 [4.3 — 5.3]	4.1 [2.9 — 4.8]	5.2 [4.8 — 5.3]	ns	0.001
HCV PCR <sup>+,1</sup> n (%)	5 (45.5)	9 (37.5)	0 (0)	0.014	0.016

Data are expressed as the median [interquartile range] of all participants unless otherwise specified.

<sup>1</sup>PCR<sup>+</sup>, PCR positive for hepatitis C virus. Chi-square and Mann-Whitney U tests were used for categorical and continuous variables respectively.


\* Differences between MCT- and control group. \*\* Differences between MCT+ and control group. **ns**: no significant.

**Supplementary Table 2. Background regimen of 12 weeks cART.**


<b>Background regimen</b>	<b>MCT- (n=11)</b>	<b>MCT+ (n=24)</b>	<b>Control Group (n=13)</b>
Two nucleoside analogs n (%)	9 (81.8)	11 (45.8)	13 (100)
No nucleoside analogs n (%)	2 (18.2)	13 (54.2)	0

## Supplementary Figure 2. Levels of soluble biomarkers baseline and after 12 weeks.

(A)



(B)



### Figure legends

Fig. S2. The results are expressed as sCD14 (A) and D-dimer (B) levels at day 0 and week 12, for every study group. Every black line represents a patient on follow up. Differences along the follow-up were studied using the Wilcoxon test; significant values are depicted with an asterisk.